Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 14/20 | 0.55 |
| ▸ | HTR2B | P41595 | 9/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 2/20 | 0.35 |
| ▸ | CD44 | P16070 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135011 | 0.85 | POLB (0.51) | HTR2CHTR2BCHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL7009040 | 0.84 | POLB (0.50) | HTR2CHTR2BCHRM4CHRM5CHRM1 | |
| SCHEMBL1528492 | 0.82 | HTR2C (0.37) | HTR2CHTR2BPOLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2874635 | 0.81 | HTR2C (0.36) | HTR2CPOLBSMN1; SMN2 | |
| SCHEMBL30648742 | 0.78 | HTR2C (0.55) | HTR2CHTR2BCHRM4CHRM5CHRM1 | |
| SCHEMBL12497623 | 0.78 | HTR2C (0.55) | HTR2CHTR2BCHRM4CHRM5CHRM1 | |
| SCHEMBL26640418 | 0.78 | HTR2C (0.55) | HTR2CHTR2BCHRM4CHRM5CHRM1 | |
| SCHEMBL24198202 | 0.77 | HTR2C (0.51) | HTR2CHTR2BCHRM4CHRM5CHRM1 | |
| SCHEMBL28949544 | 0.77 | HTR2C (0.51) | HTR2CHTR2BCHRM4CHRM5CHRM1 | |
| SCHEMBL19368147 | 0.77 | HTR2C (0.51) | HTR2CHTR2BCHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018120-A1 | MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2024-01-18 | — | — | US | disclosed |
| EP-3419972-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-07-26 | — | — | EP | disclosed |
| EP-3932404-A1 | METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2022-01-05 | — | — | EP | disclosed |
| EP-3186243-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-07-21 | — | — | EP | disclosed |
| EP-3233858-B1 | ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| US-10323032-B2 | P2X7 Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-18 | — | — | US | disclosed |
| WO-2019001572-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | 北京泰德制药股份有限公司 | 2019-01-03 | — | — | WO | disclosed |
| US-20180072724-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-15 | — | — | US | disclosed |
| US-20170266167-A1 | ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170174680-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-22 | — | — | US | disclosed |
| US-9604982-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-28 | — | — | US | disclosed |
| US-20160024082-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-01-28 | — | — | US | disclosed |
| US-9096596-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-04 | — | — | US | disclosed |
| US-20140275120-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323032-B2 | P2X7 Modulators | P2RX7, P2RX1, P2RX3 | HTR2C 503/4885HTR2B 265/4885CHRM4 261/4885 |
| US-20140275120-A1 | P2X7 MODULATORS | P2RX7, P2RX1, P2RX3 | HTR2C 458/4885HTR2B 268/4885CHRM4 207/4885 |
| US-20170266167-A1 | ERK INHIBITORS | MAPK1, MAPK3, MAPK6 | HTR2C 4319/4885HTR2B 4014/4885CHRM4 4620/4885 |
| US-20240018120-A1 | MAGL INHIBITORS | MAG, MAGI3, MAGT1 | HTR2C 3902/4885HTR2B 4091/4885CHRM4 4564/4885 |
| US-20160024082-A1 | P2X7 MODULATORS | P2RX1, P2RX5, P2RX3 | HTR2C 114/4885HTR2B 64/4885CHRM4 156/4885 |
| US-20170174680-A1 | P2X7 MODULATORS | P2RX7, P2RX1, P2RX3 | HTR2C 503/4885HTR2B 265/4885CHRM4 261/4885 |
| US-20180072724-A1 | P2X7 MODULATORS | P2RX7, P2RX1, P2RX3 | HTR2C 503/4885HTR2B 265/4885CHRM4 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.